Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer

Cancer Prevention Research

Volumn 6, Issue 4, 2013, Pages 331-338

  Wang, Wan Sheng ^a,b   Liu, Ling Xiao ^a   Li, Guo Ping ^a   Chen, Yi ^a   Li, Chang Yu ^a   Jin, Da Yong ^a   Wang, Xiao Lin ^a  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA; MICRORNA 27A 3P; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BENIGN PERIPANCREATIC DISEASE; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PANCREAS DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDIES AS TOPIC;

EID: 84877259300     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0307     Document Type: Article

References (29)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31:164-9. (Pubitemid 40214752)
4. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005;23:4524-31. (Pubitemid 46196582)
5. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol 2006;58 Suppl 1:s63-68.
6. Elmén J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencingin non-human primates. Nature 2008; 452:896-9. (Pubitemid 351550859)
7. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005; 33:1290-7. (Pubitemid 41439922)
8. Karp X, Ambros V. Developmental biology: encountering microRNAs in cell fate signaling. Science 2005;310:1288-9. (Pubitemid 41698853)
9. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6. (Pubitemid 38055775)
10. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-30. (Pubitemid 39545853)
11. Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet 2004;20:617-24. (Pubitemid 39441280)
12. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. Science 2007;316:604-8. (Pubitemid 46683147)
13. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 2007;104:1604-9. (Pubitemid 46214637)
14. Okada H, Kohanbash G, Lotze MT. MicroRN As inimmune regulation- opportunities for cancer immunotherapy. Int J Biochem Cell Biol 2010;42:1256-61.
15. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, et al. MiR-17-92 expression in differentiated T cells-implications for cancer immunotherapy. J Transl Med 2010;8:17.
16. Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. AmJ Gastroenterol 2010;105:1661-9.
17. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One 2011;6:e17014.
18. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+to analyze and compare ROC curves. BMC Bioinform 2011;12:77.
19. Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009;128: 141-9.
20. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608-11. (Pubitemid 46683148)
21. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007;129: 147-61. (Pubitemid 46507589)
22. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006;103:12481-6. (Pubitemid 44267285)
23. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70. (Pubitemid 46488663)
24. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011;56:2491-6.
25. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9.
26. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009;198:333-9.
27. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009;273:233-42.
28. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007;67:11001-11. (Pubitemid 350145930)
29. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, Safe S. MicroRNA-27a indirectly regulates estrogen receptoraexpression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology 2010; 151:2462-73.